The members of the EU-CardioRNA COST Action CA17129 have set-up a CardioRNA COVID19 Task Force aiming to organise future collaborative research on cardiovascular complications in patients infected with SARS-CoV-2.
They would like to engage and collaborate with other researchers and institutes to build a multi-centre study on cardiovascular RNA biomarkers in SARS-CoV-2-infected patients.
They believe that the Covid-19 crisis will have a longer term residual repercussions on the cardiovascular system. It will be imperative therefore to understand the mechanisms implicated and to develop clinical cardiovascular biomarkers allowing for effective future management of such patients.
The latest review article just published on behalf of the EU-CardioRNA COST Action in Basic Research in Cardiology!
The review summarizes and discusses (1) mitochondrial microRNAs (mitomiRs) and long noncoding RNAs (lncRNAs) encoded either by nuclear or mitochondrial genome which are involved in the regulation of mitochondrial metabolism; (2) the role of mitomiRs and lncRNAs in the pathogenesis of several CVD such as hypertension, cardiac hypertrophy, acute myocardial infarction and heart failure; (3) the biomarker and therapeutic potential of mitochondrial ncRNAs in CVD; (4) and the challenges inherent to their translation into clinical application.
CardioRNA COST Action CA17129 is a collaborative pan-European network of multidisciplinary researchers, clinicians, and industrial partners aiming to accelerate the understanding of transcriptomics in cardiovascular disease (CVD) and further the translation of experimental data into usable applications to improve personalized medicine in this field.